Evidence map›Paper›PMID 31707448›Full record

ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2020

Suppressors of cytokine signalling (SOCS)-1 inhibits neuroinflammation by regulating ROS and TLR4 in BV2 cells.

Jinxia Hu, Weiwei Wang, Qi Hao, Tao Zhang, Hanhan Yin, Miao Wang, Cheng Zhang, Conghui Zhang, Lijie Zhang, Xiao Zhang and 4 more

RetractedAbstract readRetracted Publication
PubMed Publisher
In one paragraph

Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Role of TLRs as signaling cascades to combat infectious diseases: a review.Cellular and molecular life sciences : CMLS · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Jinxia Hu *Institute of Stroke Center, The Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University, Xuzhou, 221002, Jiangsu, China.
Weiwei Wang *Department of Rehabilitation Medicine, The Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University, No. 99 West Huaihai Road, Xuzhou, 221006, Jiangsu, People's Republic of China.
Qi HaoInstitute of Stroke Center, The Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University, Xuzhou, 221002, Jiangsu, China.
Tao ZhangInstitute of Stroke Center, The Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University, Xuzhou, 221002, Jiangsu, China.
Hanhan YinInstitute of Stroke Center, The Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University, Xuzhou, 221002, Jiangsu, China.
Miao WangInstitute of Stroke Center, The Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University, Xuzhou, 221002, Jiangsu, China.
Cheng ZhangInstitute of Stroke Center, The Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University, Xuzhou, 221002, Jiangsu, China.
Conghui ZhangInstitute of Stroke Center, The Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University, Xuzhou, 221002, Jiangsu, China.
Lijie ZhangDepartment of Rehabilitation Medicine, The Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University, No. 99 West Huaihai Road, Xuzhou, 221006, Jiangsu, People's Republic of China.
Xiao ZhangDepartment of Rehabilitation Medicine, The Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University, No. 99 West Huaihai Road, Xuzhou, 221006, Jiangsu, People's Republic of China.
Wei WangDepartment of Rehabilitation Medicine, The Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University, No. 99 West Huaihai Road, Xuzhou, 221006, Jiangsu, People's Republic of China.
Xichuan CaoSchool of Material Science and Engineering, China University of Mining and Technology, Xuzhou, 221116, Jiangsu, People's Republic of China.
Jie XiangDepartment of Rehabilitation Medicine, The Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University, No. 99 West Huaihai Road, Xuzhou, 221006, Jiangsu, People's Republic of China. 18052268386@163.com.
Xinchun YeInstitute of Stroke Center, The Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University, Xuzhou, 221002, Jiangsu, China. xinchunye@xzhmu.edu.cn.
Xuzhou Medical College · CNChina University of Mining and Technology · CN

Funding

Fundamental Research Funds for the Central Universities 2018BSCXA12Postgraduate Research & Practice Innovation Program of Jiangsu Province KYCX18_1931Six Talent Climax Foundation of Jiangsu WSN-118the Natural Science Research of Jiangsu Higher Education Institutions of China 17KJB320017
6 · The paper itself

Abstract

objectiveThe suppressors of cytokine signaling (SOCS) proteins are physiological suppressors of cytokine signaling which have been identified as a negative feedback loop to weaken cytokine signaling. However, the underlying molecular mechanisms is unknown. This study was to investigate the role of SOCS1 in the oxygen-glucose deprivation and reoxygenation (OGDR) or LPS-induced inflammation in microglia cell line BV-2 cells. MATERIALS AND

methodsBV-2 microglial cells were used to construct inflammation model. A SOCS1 over-expression plasmid was constructed, and the SOCS1-deficient cells were generated by utilizing the CRISPR/CAS9 system. BV-2 microglial cells were pretreated with over-expression plasmid or SOCS1 CRISPR plasmid before OGDR and LPS stimulation. The effect of SOCS1 on proinflammatory cytokines, toll-like receptor 4 (TLR4), and reactive oxygen species (ROS) were evaluated.

resultsWe found that SOCS1 increased in OGDR or LPS-treated BV-2 microglial cells in vitro. SOCS1 over-expression significantly reduced the production of proinflammatory cytokines including tumor necrosis factor α (TNF-α), interleukin 1β (IL-1β), and IL-6, and CRISPR/CAS9-mediated SOCS1 knockout reversed this effect. Also we determined that SOCS1 over-expression reduced the level of reactive oxygen species (ROS) while the absence of SOCS1 increased the production of ROS after OGDR or LPS-stimulated inflammation. Furthermore, we found that OGDR and LPS induced the expression of toll-like receptor 4 (TLR4) in BV2 cells. Nevertheless, SOCS1 over-expression attenuated the expression of TLR4, while knockdown of SOCS1 upregulated TLR4.

conclusionsOur study indicated that SOCS1 played a protective role under inflammatory conditions in OGDR or LPS treated BV-2 cells through regulating ROS and TLR4. These data demonstrated that SOCS1 served as a potential therapeutic target to alleviate inflammation after ischemic stroke.

Indexed as

AnimalsCell LineCytokinesEncephalitisLipopolysaccharidesMaleMice, Inbred C57BLReactive Oxygen SpeciesSuppressor of Cytokine Signaling 1 ProteinToll-Like Receptor 4CytokinesLipopolysaccharidesReactive Oxygen SpeciesSocs1 protein, mouseSuppressor of Cytokine Signaling 1 ProteinTlr4 protein, mouseToll-Like Receptor 4Inflammation suppressor of cytokine signaling 1 (SOCS1)Lipopolysaccharide (LPS)Oxygen–glucose deprivation and reoxygenation (OGDR)Reactive oxygen species (ROS)Toll-like receptor 4 (TLR4)

Identifiers

PMID31707448
OpenAlexW3070208578

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.